News

Article

Pharma Pulse 8/5/25: GAIN Therapeutics Ramps Up for Next Big Step in Parkinson’s Drug Development; Harnessing AI to Advance Clinical Trials and Oncology Pharmacy

Key Takeaways

  • GAIN Therapeutics completed Phase Ib trial enrollment for GT-02287 early, with Phase II planned for 2026, contingent on biomarker data.
  • AI is transforming oncology by enhancing trial design, patient recruitment, and personalized care, despite data privacy and bias challenges.
SHOW MORE

GAIN Therapeutics Ramps Up for Next Big Step in Parkinson’s Drug Development

In an interview with Pharmaceutical Executive, GAIN Therapeutics CEO Gene Mack shared that enrollment for the Phase Ib trial of GT-02287—an AI-designed Parkinson’s therapy—was completed three months early, with Phase II planned for early 2026 pending promising biomarker data expected in late 2025.

Harnessing AI to Advance Clinical Trials and Oncology Pharmacy

Artificial intelligence is rapidly transforming oncology by streamlining clinical trial design, improving patient recruitment, enhancing pharmacy practice, and enabling more personalized cancer care—despite ongoing challenges around data privacy, algorithmic bias, and clinical integration.

Clinical Trial Failure Isn’t an Inevitable Risk—It’s Insurable and Opening the Door to New Investors

In an Applied Clinical Trials article, experts highlight how clinical trial failure is no longer an uninsurable risk, with emerging insurance solutions now enabling biotech companies to mitigate losses, attract new institutional investors, and build more financially resilient innovation pipelines.

Northwell Cancer Institute Names Global Oncology Researcher Geraldine O’Sullivan Coyne, MD, PhD, to lead START Unit’s Early-Stage Clinical Trials

Northwell Cancer Institute has appointed internationally recognized oncology expert Geraldine O’Sullivan Coyne to lead its new START unit, expanding early-phase cancer clinical trials to community-based settings and bringing cutting-edge therapies closer to patients with rare and complex cancers.

Just How Many Patients Have Real Psychiatric Illness? The Rise of Malingering in Emergency Psychiatry

Malingering—when patients exaggerate or fabricate psychiatric symptoms for external gain—is increasingly common in emergency psychiatry, highlighting the urgent need for clinicians to respond with honesty, empathy, and clear communication while maintaining clinical boundaries and ensuring proper care.

Newsletter

Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.

Related Videos
Related Content
© 2025 MJH Life Sciences

All rights reserved.